

SUPPORTING INFORMATION

Sulfamide Instead Urea in Biginelli Reaction: From Black Box to Reality

Alexander Yu. Lyapunov, Andriy V. Tarnovskiy, Sergey Yu. Boron, Eduard B. Rusanov, Galyna P. Grabchuk, Dmytro M. Volochnyuk,* Serhiy V. Ryabukhin*

Table of Contents

General Information	S2
Synthetic procedures	S2
Analytical data	S2
Figure S1. NMR reaction profile for 7ca	S7
Figure S2. Degradation of 7cc , 2 weeks	S7
Figure S3. Degradation of 7cd , 2 weeks	S8
Figure S4. Degradation of 7ce , 2 weeks	S8
Figure S5. Temperature NMR for 9cb	S9
Figure S6. Temperature NMR for 10cb	S9
Figure S7. Thermal profile of the initial steps of the reaction and the ¹ H NMR spectra of the reaction mixtures	S10
NMR spectra	S11

General Information

The solvents were purified according to the standard procedures. All starting materials were obtained from Enamine Ltd. Melting points were measured on automated melting point system. ¹H and ¹³C, spectra were recorded on a Bruker Avance 500 spectrometer (at 500 MHz for Protons and 126 MHz for Carbon-13) and Varian Unity Plus 400 spectrometer (at 400 MHz for protons, 101 MHz for Carbon-13, and 376 MHz for Fluorine-19). Tetramethylsilane (¹H, ¹³C) was added as an internal standard. Preparative HPLC analyses were done on an Agilent 1200 instrument. Mass spectra were recorded on Agilent 1100 LCMSD SL instrument (chemical ionization (APCI)). High-resolution mass spectra (HRMS) were obtained on an Agilent 1260 Infinity UHPLC instrument coupled with an Agilent 6224 Accurate Mass TOF mass spectrometer.

All crystallographic measurements were performed on a Bruker Smart Apex II diffractometer operating in the ω and θ scans mode with graphite-monochromated Mo-K α radiation ($\lambda = 0.71073 \text{ \AA}$). The data were corrected for Lorentz-polarization effects and for the effects of absorption (multi-scans method was applied for all compounds). The structures were solved by direct methods and refined by the full-matrix least-squares technique in the anisotropic approximation for non-hydrogen atoms using the Bruker SHELXTL program package.

Full crystallographic details have been deposited at Cambridge Crystallographic Data Centre (CCDC). Any request to the CCDC for these materials should quote the full literature citation and reference number CCDC 2252701-2252705, 2309237.

Three-component condensation. General procedure.

Corresponding acetoacetamide **2.1–2.5** (2 mmol), aldehyde **3.1–3.12** (2 mmol) and sulfamide **1.1–1.3** (2 mmol) were dissolved in DMF (2 ml). TMSCl (1.4 ml, 11 mmol) was added to the mixture under vigorous stirring in an Ar atmosphere and stirred for 24 h and 40 h for sulfamide **1.1** and **1.2**, **1.3**, correspondingly. The lower layer of the reaction mixture was separated with a syringe and further processed as indicated:

Protocol B (acidic): the solution was poured into 50 ml of stirring water, stirred for 30 minutes, the precipitate formed was filtered, washed and dried on the filter.

Protocol C (urotropine): the solution was added dropwise (2 drops/s) to a cooled to 5° solution of hexamethylenetetramine (3.75 g, 26.8 mmol) in water (15 ml) under vigorous stirring. The precipitate formed was filtered in 10–15 minutes, washed and dried on the filter.

Protocol D (morpholine): the solution was added dropwise (2 drops/s) to cooled to 5° solution of N-methylmorpholine (3.0 ml, 27.2 mmol) in of water (15 ml) under vigorous stirring. The precipitate formed was filtered in 10–15 minutes, washed and dried on the filter.

For purification, the crude products were dissolved in a minimum volume of acetone (3–5 ml), hexane was added dropwise with stirring until the precipitation formed. The product was filtered off, washed with an acetone–hexane mixture with the same ratio and dried.

Two-component condensation.

The synthesis was performed similarly to the three-component one starting from 2 mmol of **8a,d** and acetoacetamide **2.3** in 2 ml of DMF and 0.7 ml of TMSCl (5.5 mmol). Processing was performed according to protocol C or D.

Analytical data

(3*R**,4*S**)-*N,N*-diethyl-5-methyl-3-phenyl-3,4-dihydro-2*H*-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (**7ca**).

White powder, mp = 204–206 °C. Yield = 64 % (416 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.66 (d, *J* = 11.3 Hz, 1H), 7.35 (s, 5H), 4.80 (t, *J* = 10.8 Hz, 1H), 3.89 (d, *J* = 10.4 Hz, 1H), 3.27 – 3.03 (m, 2H), 3.08 – 2.91 (m, 1H), 2.93 – 2.74 (m, 1H), 2.08 (s, 3H), 0.85 (t, *J* = 6.9 Hz, 3H), 0.54 (t, *J* = 7.0 Hz, 3H). ¹³C{¹H} NMR (76 MHz, Chloroform-*d*) δ 184.6, 171.7, 141.8, 133.8, 132.4, 63.8, 54.6, 47.1, 45.1, 30.7, 18.5, 17.3. LCMS, positive mode, *m/z*: 324 [M+H]⁺. HRMS (ESI–TOF) calcd. for C₁₅H₂₂N₃O₃S⁺ [M+H]⁺: 324.1376, found 324.1374. Anal. calcd. for C₁₅H₂₁N₃O₃S: C, 55.71; H, 6.55; N, 12.99; S, 9.91. Found: C, 56.07; H, 6.82; N, 12.90; S, 9.77.

SUPPORTING INFORMATION

(3R,4S*)-5-methyl-N,3-diphenyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7da)*

Thin white needles, mp = 186–190 °C. Yield = 21% (144 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.43 (s, 1H), 7.73 (d, *J* = 12.0 Hz, 1H), 7.42 (d, *J* = 7.4 Hz, 2H), 7.39 – 7.30 (m, 5H), 7.26 (t, *J* = 7.8 Hz, 2H), 7.06 (t, *J* = 7.4 Hz, 1H), 4.89 (t, *J* = 11.4 Hz, 1H), 3.85 (d, *J* = 10.9 Hz, 1H), 2.20 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 179.4, 166.0, 138.1, 137.1, 129.3, 129.1, 129.0, 127.9, 124.8, 120.1, 58.1, 53.8, 26.0. LCMS, positive mode, *m/z*: 344 [M+H]⁺. HRMS (ESI–TOF) calcd. for C₁₇H₁₈N₃O₃S⁺ [M+H]⁺: 344.1063, found 344.1062. Anal. calcd. for C₁₇H₁₇N₃O₃S: C, 59.46; H, 4.99; N, 12.24; S, 9.34. Found: C, 59.81; H, 5.29; N, 12.58; S, 9.12.

(3R,4S*)-N,5-dimethyl-N,3-diphenyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7ea)*

Light-gray powder, mp = 200–205 °C. Yield = 50% (357 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.52 – 7.35 (m, 5H), 7.37 – 7.26 (m, 2H), 7.28 – 7.08 (m, 4H), 4.79 (d, *J* = 10.4 Hz, 1H), 3.40 (d, *J* = 10.5 Hz, 1H), 3.04 (s, 3H), 2.18 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 179.1, 167.5, 142.4, 136.9, 130.2, 129.3, 129.2, 128.8, 127.7, 127.5, 58.8, 50.5, 37.8, 26.7. LCMS, positive mode, *m/z*: 358 [M+H]⁺. HRMS (ESI–TOF) calcd. for C₁₈H₂₀N₃O₃S⁺ [M+H]⁺: 358.1220, found 358.1220. Anal. calcd. for C₁₈H₁₉N₃O₃S: C, 60.49; H, 5.36; N, 11.76; S, 8.97. Found: C, 60.54; H, 5.43; N, 11.67; S, 8.67.

(3R,4S*)-3-(4-methoxyphenyl)-N,N,5-trimethyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7bb)*

White powder, mp = 165–168 °C. Yield = 14% (91 mg). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.58 (d, *J* = 11.3 Hz, 1H), 7.27 (d, *J* = 8.6 Hz, 2H), 6.92 (d, *J* = 8.6 Hz, 2H), 4.64 (t, *J* = 10.8 Hz, 1H), 4.02 (d, *J* = 10.5 Hz, 1H), 3.74 (s, 3H), 2.69 (s, 3H), 2.55 (s, 3H), 2.08 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 180.2, 168.1, 159.7, 129.0, 128.9, 114.4, 58.5, 55.6, 49.6, 37.7, 35.7, 26.0. LCMS, positive mode, *m/z*: 326 [M+H]⁺. HRMS (ESI–TOF) calcd. for C₁₄H₂₀N₃O₄S⁺ [M+H]⁺: 326.1169, found 326.1167. Anal. calcd. for C₁₄H₁₉N₃O₄S: C, 51.68; H, 5.89; N, 12.91; S, 9.85. Found: C, 51.42; H, 5.99; N, 13.02; S, 9.95.

(3R,4S*)-N,N-diethyl-3-(4-methoxyphenyl)-5-methyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7cb)*

Colorless crystalline powder, mp = 180–184 °C. Yield = 45% (317 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.56 (s, 1H), 7.26 (d, *J* = 8.3 Hz, 2H), 6.90 (d, *J* = 8.2 Hz, 2H), 4.72 (d, *J* = 10.2 Hz, 1H), 3.87 (d, *J* = 10.4 Hz, 1H), 3.71 (s, 3H), 3.31 – 3.06 (m, 2H), 3.08 – 2.77 (m, 2H), 2.07 (s, 3H), 0.86 (t, *J* = 7.0 Hz, 3H), 0.61 (t, *J* = 7.0 Hz, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 184.7, 171.9, 164.5, 134.0, 133.8, 119.1, 63.2, 60.3, 54.7, 47.0, 45.1, 30.7, 18.6, 17.3. LCMS, positive mode, *m/z*: 354 [M+H]⁺. HRMS (ESI–TOF) calcd. for C₁₆H₂₄N₃O₄S⁺ [M+H]⁺: 354.1482, found 354.1479. Anal. calcd. for C₁₆H₂₃N₃O₄S: C, 54.37; H, 6.56; N, 11.89; S, 9.07. Found: C, 54.26; H, 6.82; N, 11.68; S, 8.80.

(3R,4S*)-3-(4-methoxyphenyl)-5-methyl-N-phenyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7db)*

White powder, mp = 186–190 °C. Yield = 44% (328 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 10.43 (s, 1H), 7.62 (d, *J* = 11.9 Hz, 1H), 7.36 (dd, *J* = 11.9, 8.2 Hz, 4H), 7.25 (t, *J* = 7.8 Hz, 2H), 7.04 (t, *J* = 7.4 Hz, 1H), 6.88 (d, *J* = 8.3 Hz, 2H), 4.83 (t, *J* = 11.4 Hz, 1H), 3.83 (d, *J* = 10.9 Hz, 1H), 3.68 (s, 3H), 2.19 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 179.4, 166.2, 159.6, 138.2, 129.3, 129.2, 124.8, 120.1, 114.4, 57.5, 55.5, 53.9, 26.0. LCMS, positive mode, *m/z*: 374 [M+H]⁺. HRMS (ESI–TOF) calcd. for C₁₈H₁₉N₃O₄S⁺ [M+H]⁺: 374.1169, found 374.1167. Anal. calcd. for C₁₈H₁₉N₃O₄S: C, 57.90; H, 5.13; N, 11.25; S, 8.59. Found: C, 57.61; H, 5.07; N, 11.03; S, 8.91.

(3R,4S*)-3-(4-methoxyphenyl)-N,5-dimethyl-N-phenyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7eb)*

White powder, mp = 173–175 °C. Yield = 50% (386 mg). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.40 – 7.25 (m, 5H), 7.09 (d, *J* = 8.3 Hz, 2H), 6.96 (d, *J* = 8.5 Hz, 2H), 4.72 (t, *J* = 10.9 Hz, 1H), 3.81 (s, 3H), 3.39 (d, *J* = 10.4 Hz, 1H), 3.06 (s, 3H), 2.17 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 183.8, 172.3, 164.7, 147.2, 134.9, 133.8, 133.5, 132.3, 119.2, 63.0, 60.5, 55.4, 42.5, 31.4. LCMS, negative mode, *m/z*: 386 [M]⁻. HRMS (ESI–TOF) calcd. for C₁₉H₂₂N₃O₄S⁺ [M+H]⁺: 388.1326, found 388.1317. Anal. calcd. for C₁₉H₂₁N₃O₄S: C, 58.90; H, 5.46; N, 10.85; S, 8.27. Found: C, 59.25; H, 5.80; N, 11.00; S, 8.59.

(3R,4S*)-3-(3,4-dimethoxyphenyl)-N,N,5-trimethyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7bc)*

Colorless crystals, mp = 192–194 °C. Yield = 48% (340 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.59 (d, *J* = 10.9 Hz, 1H), 7.06 (s, 1H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.81 (dd, *J* = 8.2, 2.0 Hz, 1H), 4.64 (t, *J* = 10.7 Hz, 1H), 4.06 (d, *J* = 10.5 Hz, 1H), 3.75 (s, 6H), 2.72 (s, 3H), 2.57 (s, 3H), 2.09 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 180.8, 168.8, 149.8, 149.8, 129.9, 120.6, 112.4, 111.6, 59.4, 56.6, 56.5, 50.2, 38.4, 36.3, 26.6. LCMS, negative mode, *m/z*: 354 [M-H]⁻. HRMS (ESI–TOF) calcd. for C₁₅H₂₂N₃O₅S⁺ [M+H]⁺: 356.1275, found 356.1281. Anal. calcd. for C₁₅H₂₁N₃O₅S: C, 50.69; H, 5.96; N, 11.82; S, 9.02. Found: C, 50.68; H, 5.77; N, 11.89; S, 8.88.

(3R,4S*)-3-(3,4-dimethoxyphenyl)-N,N-diethyl-5-methyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7cc)*

White powder, mp = 173–176 °C. Yield = 49% (375 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.56 (d, *J* = 10.6 Hz, 1H), 7.04 (s, 1H), 6.96 – 6.73 (m, 2H), 4.71 (t, *J* = 10.5 Hz, 1H), 3.90 (d, *J* = 10.4 Hz, 1H), 3.71 (d, *J* = 3.7 Hz, 6H), 3.23 – 3.08 (m, 2H), 3.11 – 2.80 (m, 2H), 2.07 (s, 3H), 0.86 (t, *J* = 7.0 Hz, 3H), 0.59 (t, *J* = 7.0 Hz, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 180.5, 167.8, 149.9, 130.1, 120.9, 112.5, 111.8, 59.4, 56.6, 50.5, 43.0, 41.1, 26.6, 14.5, 13.2. LCMS, negative mode, *m/z*: 382 [M-H]⁻. HRMS (ESI–TOF) calcd. for C₁₇H₂₆N₃O₅S⁺ [M+H]⁺: 384.1588, found 384.1586. Anal. calcd. for C₁₇H₂₅N₃O₅S: C, 53.25; H, 6.57; N, 10.96; S, 8.36. Found: C, 53.50; H, 6.69; N, 11.09; S, 8.40.

(3R,4S*)-3-(4-bromophenyl)-N,N,5-trimethyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7bd)*

White powder, mp = 183–187 °C. Yield = 12% (90 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.74 (d, *J* = 10.4 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 8.1 Hz, 2H), 4.72 (t, *J* = 10.6 Hz, 1H), 4.05 (d, *J* = 10.5 Hz, 1H), 2.70 (s, 3H), 2.57 (s, 3H), 2.09 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 180.6, 168.4, 136.8, 132.7, 130.4, 123.0, 59.1, 49.8, 38.4, 36.3, 26.6. LCMS, negative mode, *m/z*: 374 [M]⁻. HRMS (ESI–TOF) calcd. for C₁₃H₁₇BrN₃O₃S⁺ [M+H]⁺: 374.0169, found 374.0169. Anal. calcd. for C₁₃H₁₆BrN₃O₃S: C, 41.72; H, 4.31; N, 11.23; S, 8.57; Br, 21.35. Found: C, 41.71; H, 4.50; N, 11.17; S, 8.29; Br, 21.01.

(3R,4S*)-3-(4-bromophenyl)-N,N-diethyl-5-methyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7cd)*

SUPPORTING INFORMATION

White powder, mp = 193–196 °C. Yield = 29% (239 mg). ^1H NMR (302 MHz, DMSO- d_6) δ 7.72 (d, J = 11.2 Hz, 1H), 7.58 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 4.79 (t, J = 10.8 Hz, 1H), 3.89 (d, J = 10.4 Hz, 1H), 3.23 – 3.09 (m, 2H), 3.13 – 2.99 (m, 1H), 2.88 (dq, J = 14.3, 7.0 Hz, 1H), 2.08 (s, 3H), 0.86 (t, J = 7.0 Hz, 3H), 0.58 (t, J = 7.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, Chloroform- d) δ 184.5, 171.6, 141.1, 136.8, 134.7, 127.0, 63.2, 54.3, 47.1, 45.2, 30.7, 18.6, 17.3. LCMS, positive mode, m/z : 402 [M] $^+$. HRMS (ESI–TOF) calcd. for $\text{C}_{15}\text{H}_{21}\text{BrN}_3\text{O}_3\text{S}^+$ [M+H] $^+$: 402.0482, found 402.0474. Anal. calcd. for $\text{C}_{15}\text{H}_{20}\text{BrN}_3\text{O}_3\text{S}$: C, 44.78; H, 5.01; N, 10.44; S, 7.97; Br, 19.86. Found: C, 44.98; H, 4.82; N, 10.27; S, 8.08; Br, 19.74.

(3R,4S*)-3-(4-bromophenyl)-N,5-dimethyl-N-phenyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7ed)*

White powder, mp = 178–180 °C. Yield = 35% (305 mg). ^1H NMR (302 MHz, DMSO- d_6) δ 7.62 (d, J = 8.0 Hz, 2H), 7.52 – 7.19 (m, 5H), 7.12 (d, J = 8.1 Hz, 2H), 6.38 (br, 1H), 4.76 (t, J = 10.6 Hz, 1H), 3.44 (d, J = 10.5 Hz, 1H), 3.07 (s, 3H), 2.19 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 179.0, 167.4, 142.4, 136.2, 132.2, 130.2, 129.9, 128.8, 127.4, 122.5, 58.3, 50.2, 37.8, 26.8. LCMS, negative mode, m/z : 434 [M-H] $^-$. HRMS (ESI–TOF) calcd. for $\text{C}_{18}\text{H}_{19}\text{BrN}_3\text{O}_3\text{S}^+$ [M+H] $^+$: 436.0325, found 436.0326. Anal. calcd. for $\text{C}_{18}\text{H}_{18}\text{BrN}_3\text{O}_3\text{S}$: C, 49.55; H, 4.16; N, 9.63; S, 7.35; Br, 18.31. Found: C, 49.31; H, 4.15; N, 9.89; S, 7.59; Br, 18.42.

(3R,4S*)-N,N-diethyl-5-methyl-3-(4-nitrophenyl)-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7ce)*

Yellowish powder. Crude. ^1H NMR (400 MHz, DMSO- d_6) δ 8.25 (d, J = 8.5 Hz, 2H), 7.91 (s, 1H), 7.65 (d, J = 8.4 Hz, 2H), 4.98 (d, J = 10.4 Hz, 1H), 3.97 (d, J = 10.4 Hz, 1H), 3.24 – 3.11 (m, 2H), 3.14 – 2.79 (m, 2H), 2.11 (s, 3H), 0.87 (t, J = 7.0 Hz, 3H), 0.57 (t, J = 7.0 Hz, 3H). LCMS, positive mode, m/z : 369 [M+H] $^+$. HRMS (ESI–TOF) calcd. for $\text{C}_{15}\text{H}_{21}\text{N}_4\text{O}_5\text{S}^+$ [M+H] $^+$: 369.1227, found 369.1221.

(3R,4S*)-3-(2-bromophenyl)-N,N-diethyl-5-methyl-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7cf)*

White powder, mp = 169–171 °C. Yield = 25% (201 mg). ^1H NMR (400 MHz, DMSO- d_6) δ 7.80 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.57 – 7.43 (m, 2H), 7.30 (t, J = 7.7 Hz, 1H), 5.45 (t, J = 8.9 Hz, 1H), 4.20 (dd, J = 10.9, 2.9 Hz, 1H), 3.29 – 3.17 (m, 1H), 3.05 (p, J = 7.3 Hz, 3H), 2.10 (t, J = 2.0 Hz, 3H), 0.82 (t, J = 7.0 Hz, 3H), 0.73 (t, J = 7.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 180.0, 166.3, 136.5, 133.4, 131.2, 130.2, 128.8, 123.9, 57.3, 48.3, 42.4, 40.0, 26.1, 14.2, 12.5. LCMS, negative mode, m/z : 402 [M-H] $^-$. HRMS (ESI–TOF) calcd. for $\text{C}_{15}\text{H}_{21}\text{BrN}_3\text{O}_3\text{S}^+$ [M+H] $^+$: 402.0482, found 402.0480. Anal. calcd. for $\text{C}_{15}\text{H}_{20}\text{BrN}_3\text{O}_3\text{S}$: C, 44.78; H, 5.01; N, 10.44; S, 7.97; Br, 19.86. Found: C, 44.77; H, 5.00; N, 10.19; S, 7.99; Br, 20.10.

(3R,4S*)-N,N-diethyl-5-methyl-3-(thiophen-3-yl)-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7ci)*

Grey powder, mp = 196–199 °C. Yield = 39% (257 mg). ^1H NMR (302 MHz, DMSO- d_6) δ 7.65 (d, J = 11.6 Hz, 1H), 7.54 (dd, J = 5.1, 2.9 Hz, 1H), 7.45 (s, 1H), 7.14 (d, J = 5.0 Hz, 1H), 4.92 (t, J = 11.0 Hz, 1H), 3.83 (d, J = 10.3 Hz, 1H), 3.19 (q, J = 7.5 Hz, 2H), 3.15 – 3.03 (m, 1H), 2.91 (dq, J = 14.2, 6.7 Hz, 1H), 2.07 (s, 3H), 0.90 (t, J = 7.0 Hz, 3H), 0.63 (t, J = 7.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 179.8, 167.2, 138.0, 127.7, 127.0, 124.4, 54.8, 49.6, 42.4, 26.1, 13.9, 12.7. LCMS, positive mode, m/z : 330 [M+H] $^+$. HRMS (ESI–TOF) calcd. for $\text{C}_{13}\text{H}_{20}\text{N}_3\text{O}_3\text{S}_2^+$ [M+H] $^+$: 330.0941, found 330.0937. Anal. calcd. for $\text{C}_{13}\text{H}_{19}\text{N}_3\text{O}_3\text{S}_2$: C, 47.40; H, 5.81; N, 12.76; S, 19.46. Found: C, 47.71; H, 5.46; N, 13.00; S, 19.51.

(3R,4S*)-N,N-diethyl-5-methyl-3-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7cj)*

White powder, mp = 161–165 °C. Yield = 35% (229 mg). ^1H NMR (500 MHz, DMSO- d_6) δ 7.60 (d, J = 3.3 Hz, 1H), 7.53 (dd, J = 11.6, 3.2 Hz, 1H), 7.38 (d, J = 3.3 Hz, 1H), 4.81 – 4.68 (m, 1H), 3.83 – 3.78 (m, 1H), 3.76 (d, J = 3.3 Hz, 3H), 3.27 – 3.15 (m, 3H), 3.12 – 2.96 (m, 1H), 2.06 (d, J = 3.3 Hz, 3H), 0.93 (td, J = 7.0, 3.3 Hz, 3H), 0.72 (td, J = 7.2, 3.2 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 179.8, 167.3, 137.5, 129.7, 117.9, 51.0, 49.9, 42.6, 26.1, 14.0, 12.6. LCMS, positive mode, m/z : 328 [M+H] $^+$. HRMS (ESI–TOF) calcd. for $\text{C}_{13}\text{H}_{20}\text{N}_3\text{O}_3\text{S}_2^+$ [M+H] $^+$: 330.0941, found 330.0937. Anal. calcd. for $\text{C}_{13}\text{H}_{21}\text{N}_5\text{O}_3\text{S}$: C, 47.69; H, 6.47; N, 21.39; S, 9.79. Found: C, 47.30; H, 6.62; N, 21.51; S, 10.05.

(3R,4S*)-N,N-diethyl-5-methyl-3-(5-methylfuran-2-yl)-3,4-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (7ck)*

White powder, mp = 169–171 °C. Yield = 36% (236 mg). ^1H NMR (500 MHz, DMSO- d_6) δ 7.65 (d, J = 7.9 Hz, 1H), 6.28 (d, J = 3.2 Hz, 1H), 6.04 (d, J = 3.1 Hz, 1H), 4.82 (t, J = 9.5 Hz, 1H), 4.00 (d, J = 10.4 Hz, 1H), 3.31 – 3.08 (m, 4H), 2.21 (s, 3H), 2.08 (s, 3H), 0.93 (t, J = 7.0 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 179.5, 166.8, 152.3, 148.1, 109.8, 107.2, 52.8, 47.3, 42.5, 26.1, 14.1, 13.7, 12.7. LCMS, negative mode, m/z : 326 [M-H] $^-$. HRMS (ESI–TOF) calcd. for $\text{C}_{14}\text{H}_{22}\text{N}_3\text{O}_4\text{S}^+$ [M+H] $^+$: 328.1326, found 328.1324. Anal. calcd. for $\text{C}_{14}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$: C, 51.36; H, 6.47; N, 12.83; S, 9.79. Found: C, 51.41; H, 6.14; N, 12.72; S, 9.61.

(S)-2-((R*)-(3,4-dimethoxyphenyl)(sulfamoylamino)methyl)-N,N-diethyl-3-oxobutanamide (8cc)*

White powder, mp = 125–129 °C. Yield = 43% (345 mg). ^1H NMR (302 MHz, DMSO- d_6) δ 7.29 (d, J = 10.9 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 6.97 – 6.69 (m, 2H), 6.41 (s, 2H), 4.93 (t, J = 11.0 Hz, 1H), 3.90 (d, J = 11.1 Hz, 1H), 3.69 (d, J = 9.5 Hz, 6H), 3.23 – 2.78 (m, 4H), 2.31 (s, 3H), 0.83 (t, J = 7.0 Hz, 3H), 0.66 (t, J = 7.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 205.1, 165.7, 149.1, 148.8, 133.6, 121.2, 112.3, 111.9, 65.2, 58.7, 56.4, 56.4, 55.9, 42.5, 27.4, 15.2, 13.5. HRMS (ESI–TOF) calcd. for $\text{C}_{17}\text{H}_{27}\text{N}_3\text{NaO}_6\text{S}^+$ [M+Na] $^+$: 424.1513, found 424.1510. Anal. calcd. for $\text{C}_{17}\text{H}_{27}\text{N}_3\text{O}_6\text{S}$: C, 50.86; H, 6.78; N, 10.47; S, 7.99. Found: C, 50.92; H, 6.49; N, 10.07; S, 7.83.

(S)-2-((R*)-(4-bromophenyl)(sulfamoylamino)methyl)-3-oxo-N-phenylbutanamide (8dd)*

White powder, mp = 160–163 °C. Yield = 30% (253 mg). ^1H NMR (302 MHz, DMSO- d_6) δ 10.09 (s, 1H), 7.67 (d, J = 10.1 Hz, 1H), 7.50 – 7.29 (m, 6H), 7.19 (t, J = 7.8 Hz, 2H), 6.98 (t, J = 7.4 Hz, 1H), 6.51 (s, 2H), 5.00 (t, J = 10.8 Hz, 1H), 3.89 (d, J = 11.3 Hz, 1H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (76 MHz, DMSO- d_6) δ 202.7, 164.3, 140.4, 138.6, 131.1, 130.5, 129.0, 124.3, 120.8, 120.0, 68.4, 56.9, 28.3. LCMS, positive mode, m/z : 440 [M+H] $^+$. HRMS (ESI–TOF) calcd. for $\text{C}_{17}\text{H}_{18}\text{BrN}_3\text{NaO}_4\text{S}^+$ [M+Na] $^+$: 462.0094, found 462.0092. Anal. calcd. for $\text{C}_{17}\text{H}_{18}\text{BrN}_3\text{O}_4\text{S}$: C, 46.37; H, 4.12; N, 9.54; S, 7.28; Br, 18.15. Found: C, 46.18; H, 3.96; N, 9.25; S, 7.63; Br, 17.91.

(S)-2-((R*)-(4-nitrophenyl)(sulfamoylamino)methyl)-3-oxo-N-phenylbutanamide (8de)*

SUPPORTING INFORMATION

Yellowish powder, mp = 175–179 °C. Yield = 30% (245 mg). ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.12 (s, 1H), 8.11 (d, *J* = 8.2 Hz, 2H), 7.84 (d, *J* = 10.0 Hz, 1H), 7.68 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 7.9 Hz, 2H), 7.18 (t, *J* = 7.8 Hz, 2H), 6.98 (t, *J* = 7.4 Hz, 1H), 6.59 (s, 2H), 5.13 (t, *J* = 10.6 Hz, 1H), 3.93 (d, *J* = 11.4 Hz, 1H), 2.36 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 202.7, 164.6, 149.4, 147.7, 139.1, 130.2, 129.6, 125.0, 124.0, 120.6, 68.4, 57.4, 29.0. LCMS, negative mode, *m/z*: 405 [M-H]⁻. HRMS (ESI-TOF) calcd. for C₁₇H₁₈N₄NaO₆S⁻ [M+Na]⁻: 429.0839, found 429.0837. Anal. calcd. for C₁₇H₁₈N₄O₆S: C 50.24; H 4.46; N 13.79; S 7.89. Found: C 50.64; H 4.52; N 13.99; S 7.81.

Ethyl 3-(4-methoxyphenyl)-5,6-dimethyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylate 1,1-dioxide (9ab)

Light yellow oil. Yield = 9% (61 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.96 (d, *J* = 7.8 Hz, 1H), 7.18 (d, *J* = 8.3 Hz, 2H), 6.83 (d, *J* = 8.2 Hz, 2H), 5.28 (d, *J* = 7.6 Hz, 1H), 3.79 (q, *J* = 7.1 Hz, 2H), 3.69 (s, 3H), 3.11 (s, 3H), 2.29 (s, 3H), 0.80 (t, *J* = 7.0 Hz, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 166.6, 159.2, 148.4, 131.2, 129.8, 113.7, 108.0, 60.0, 58.4, 55.5, 32.0, 17.6, 14.0. LCMS, positive mode, *m/z*: 341 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₁₅H₂₁N₂O₅S⁺ [M+H]⁺: 341.1166, found 341.1164. Anal. calcd. for C₁₅H₂₀N₂O₅S: C, 52.93; H, 5.92; N, 8.23; S, 9.42. Found: C, 53.31; H, 5.91; N, 8.61; S, 9.18.

N,N-diethyl-3-(4-methoxyphenyl)-5,6-dimethyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (9cb)

White powder, mp = 155–157 °C. Yield = 51% (375 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 7.69 (dd, *J* = 51.5, 7.2 Hz, 1H), 7.28 (d, *J* = 8.3 Hz, 2H), 6.83 (dd, *J* = 11.6, 8.2 Hz, 2H), 5.31 – 4.73 (m, 1H), 3.70 (s, 3H), 3.29 – 3.06 (m, 2H), 3.02 (s, 3H), 2.98 – 2.73 (m, 2H), 1.90 – 1.67 (m, 3H), 1.08 (t, *J* = 7.0 Hz, 1H), 0.72 (t, *J* = 6.9 Hz, 2H), 0.65 (t, *J* = 6.2 Hz, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 166.6, 165.9*, 159.1, 136.3*, 134.0, 130.3*, 129.4, 128.8*, 128.3, 118.8*, 117.9, 113.5, 113.1*, 60.2*, 60.0, 55.2, 55.1*, 41.4*, 41.2, 37.5*, 36.6, 34.2, 17.7, 14.4*, 12.8, 12.1*, 11.7 (* - due to hindered rotation). LCMS, positive mode, *m/z*: 368 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₁₇H₂₆N₃O₄S⁺ [M+H]⁺: 368.1639, found 368.1635. Anal. calcd. for C₁₇H₂₅N₃O₄S: C, 55.57; H, 6.86; N, 11.44; S, 8.72. Found: C, 55.39; H, 6.88; N, 11.08; S, 8.41.

3-(4-methoxyphenyl)-5,6-dimethyl-N-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (9db)

White powder. Yield = 15% (116 mg). ¹H NMR (302 MHz, DMSO-*d*₆) δ 9.86 (s, 1H), 7.72 (d, *J* = 7.4 Hz, 1H), 7.36 (dd, *J* = 13.8, 8.2 Hz, 4H), 7.18 (t, *J* = 7.8 Hz, 2H), 6.95 (t, *J* = 7.4 Hz, 1H), 6.78 (d, *J* = 8.3 Hz, 2H), 5.38 (d, *J* = 7.0 Hz, 1H), 3.65 (s, 3H), 3.06 (s, 3H), 2.06 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 166.1, 159.3, 139.8, 139.1, 130.5, 130.2, 128.9, 123.9, 120.1, 117.0, 113.6, 59.4, 55.4, 33.4, 18.5. LCMS, negative mode, *m/z*: 386 [M-H]⁻. HRMS (ESI-TOF) calcd. for C₁₉H₂₂N₃O₄S⁻ [M+H]⁻: 388.1326, found 388.1321. Anal. calcd. for C₁₉H₂₁N₃O₄S: C, 58.90; H, 5.46; N, 10.85; S, 8.27. Found: C, 59.23; H, 5.76; N, 10.79; S, 8.49.

5,6-dimethyl-3-(4-nitrophenyl)-N-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (9de)

White powder, mp = 169–172 °C. Yield = 35% (283 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.07 (s, 1H), 8.22 (d, *J* = 4.2 Hz, 1H), 8.14 (d, *J* = 8.5 Hz, 2H), 7.74 (d, *J* = 8.5 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.22 (t, *J* = 7.8 Hz, 2H), 7.00 (t, *J* = 7.4 Hz, 1H), 5.65 (s, 1H), 3.13 (s, 3H), 2.17 (s, 3H). ¹³C{¹H} NMR (76 MHz, DMSO-*d*₆) δ 165.5, 147.0, 145.8, 141.1, 138.5, 130.0, 128.6, 123.6, 123.0, 119.6, 113.6, 58.0, 32.5, 18.1. LCMS, positive mode, *m/z*: 403 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₁₈H₁₉N₄O₅S⁺ [M+H]⁺: 403.1071, found 403.1066. Anal. calcd. for C₁₈H₁₈N₄O₅S: C, 53.72; H, 4.51; N, 13.92; S, 7.97. Found: C, 53.32; H, 4.37; N, 13.97; S, 7.93.

N,N-diethyl-3-(4-methoxyphenyl)-5-methyl-6-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxamide 1,1-dioxide (10cb)

White powder, mp = 187–190 °C. Yield = 56% (481 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.03 (dd, *J* = 55.2, 7.1 Hz, 1H), 7.51 (t, *J* = 7.2 Hz, 2H), 7.46 – 7.32 (m, 5H), 6.89 (dd, *J* = 15.1, 8.3 Hz, 2H), 5.21 (dd, *J* = 74.5, 7.0 Hz, 1H), 3.74 (d, *J* = 4.0 Hz, 3H), 3.54 – 3.34 (m, 1H), 3.29 – 2.84 (m, 3H), 1.62 – 1.42 (m, 3H), 1.14 (t, *J* = 6.9 Hz, 1H), 0.76 (t, *J* = 7.0 Hz, 1H), 0.69 (q, *J* = 6.8 Hz, 4H). LCMS, positive mode, *m/z*: 430 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₂₂H₂₈N₃O₄S⁺ [M+H]⁺: 430.1795, found 430.1792. Anal. calcd. for C₂₂H₂₇N₃O₄S: C, 61.52; H, 6.34; N, 9.78; S, 7.46. Found: C, 61.85; H, 6.07; N, 9.89; S, 7.09.

(S)-2-((R*)-(4-bromophenyl)((N-methylsulfamoyl)amino)methyl)-3-oxo-N-phenylbutanamide (11dd)*

White powder, mp = 146–151 °C. Yield = 18% (164 mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.10 (s, 1H), 7.87 (d, *J* = 10.0 Hz, 1H), 7.45 (d, *J* = 8.5 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.20 (t, *J* = 7.8 Hz, 2H), 6.99 (t, *J* = 7.4 Hz, 1H), 6.67 (q, *J* = 5.0 Hz, 1H), 4.86 (t, *J* = 10.5 Hz, 1H), 3.97 (d, *J* = 11.0 Hz, 1H), 2.34 (s, 3H), 2.05 (d, *J* = 5.0 Hz, 3H). ¹³C NMR (76 MHz, DMSO-*d*₆) δ 201.8, 163.6, 139.8, 138.1, 130.6, 130.0, 128.6, 123.8, 120.5, 119.5, 67.4, 56.3, 28.4, 27.7. LCMS, negative mode, *m/z*: 452 [M-H]⁻. HRMS (ESI-TOF) calcd. for C₁₈H₂₁BrN₃O₄S⁻ [M+H]⁻: 454.0431, found 454.0425. Anal. calcd. for C₁₈H₂₀BrN₃O₄S: C, 47.58; H, 4.44; N, 9.28; S, 7.06; Br, 17.59. Found: C, 47.98; H, 4.54; N, 9.18; S, 7.12; Br, 17.95.

N-(4-methoxybenzylidene)sulfamide (12b)

White powder, mp = 169–171 °C. Yield = 41% (0.88 g). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.81 (s, 1H), 7.93 (d, *J* = 8.7 Hz, 2H), 7.24 (s, 2H), 7.11 (d, *J* = 8.7 Hz, 2H), 3.85 (s, 3H). ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) δ 165.86, 164.09, 132.64, 125.13, 114.85, 55.68. LCMS, positive mode, *m/z*: 215 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₈H₁₁N₂O₃S⁺ [M+H]⁺: 215.0485, found 215.0483. Anal. calcd. for C₈H₁₀N₂O₃S: C 44.85; H 4.70; N 13.08; S 14.97. Found: C 44.32; H 4.37; N 13.17; S 14.93.

N-(4-bromobenzylidene)sulfamide (12d)

White powder, mp = 241–243 °C. Yield = 9% (0.238 g). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.91 (s, 1H), 7.92 (d, *J* = 8.2 Hz, 2H), 7.79 (d, *J* = 8.2 Hz, 2H), 7.37 (br. s, 2H). ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) δ 192.28, 165.78, 132.45, 132.05, 128.13. LCMS, positive mode, *m/z*: 263 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₇H₇BrN₂O₂S⁺ [M+H]⁺: 262.9484, found 262.9474. Anal. calcd. for C₇H₇BrN₂O₂S: C 31.95; H 2.68; Br 30.37, N 10.65; S 12.19. Found: C 32.15; H 2.73; Br 30.12, N 10.34; S 12.29.

N-(4-methoxybenzylidene)-N'-methylsulfamide (14b)

White powder, mp = 115–117 °C. Yield = 41% (2.09 g). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (s, 1H), 7.98 (d, *J* = 8.5 Hz, 2H), 7.87 (br. d, *J* = 4.7 Hz, 1H), 7.12 (d, *J* = 8.5 Hz, 2H), 3.87 (s, 3H), 2.55 (d, *J* = 5.2 Hz, 3H). ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) δ 168.09,

SUPPORTING INFORMATION

164.34, 132.93, 125.06, 114.83, 55.72, 29.01. LCMS, positive mode, m/z: 229 [M+H]⁺. HRMS (ESI-TOF) calcd. for C₉H₁₃N₂O₃S⁺ [M+H]⁺: 229.0641, found 229.0638. Anal. calcd. for C₉H₁₂N₂O₃S: C 47.35; H 5.50; N 12.27; S 14.05. Found: C 47.46; H 5.37; N 12.17; S 14.03.

(3S,7S*)-2,6-dimethyl-3,7-bis(4-nitrophenyl)-1,5,2,4,6,8-dithiatetrazocane 1,1,5,5-tetraoxide (15e)*

Yellow crystalline powder. Yield = 30% (147mg). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.47 (d, *J* = 10.6 Hz, 1H), 8.35 (d, *J* = 9.3 Hz, 2H), 7.70 (d, *J* = 8.5 Hz, 2H), 6.59 (d, *J* = 10.5 Hz, 1H), 3.34 (s, 3H), 2.63 (s, 3H). LCMS, negative mode, m/z: 485 [M-H]⁻. HRMS (ESI-TOF) calcd. for C₁₆H₁₉N₆O₈S₂⁺ [M+H]⁺: 487.0700, found 487.0691. Anal. calcd. for C₁₄H₁₇N₃O₆S: C, 47.32; H, 4.82; N, 11.82; S, 9.02. Found: C, 47.09; H, 4.79; N, 11.66; S, 8.99.

SUPPORTING INFORMATION

Figure S1. NMR reaction profile for **7ca**.





Figure S2. Degradation of **7cc**, 2 weeks.



SUPPORTING INFORMATION

Figure S3. Degradation of **7cd**, 2 weeks.





Figure S4. Degradation of **7ce**, 2 weeks.



SUPPORTING INFORMATION

Figure S5. Temperature NMR for **9cb**.






Figure S6. Temperature NMR for **10cb**.



SUPPORTING INFORMATION


Figure S7. Thermal profile of the initial steps of the reaction and the ^1H NMR spectra of the reaction mixtures (the time scale in hours).




SUPPORTING INFORMATION

NMR spectra

¹H and ¹³C NMR spectra of the compound 7ca




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7da




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7ea




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7bb

van-lay1802




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7cb

LAY_17_1H




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7db




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7eb

van-lay241.1.fid




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7bc

van-lay195




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7cc
lay_20_1H




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7bd




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR of the compound 7cd




SUPPORTING INFORMATION



SUPPORTING INFORMATION


¹H and ¹³C NMR spectra of the compound 7ed

LAY-06_1H



SUPPORTING INFORMATION


LAY-06_13C
13C



SUPPORTING INFORMATION

¹H NMR spectrum of the compound 7ce


van-lay071.1.fid




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7cf

van-lay313.1.fid




SUPPORTING INFORMATION



SUPPORTING INFORMATION


¹H and ¹³C NMR spectra of the compound 7ci

LAY_27_1H



SUPPORTING INFORMATION


LAY_27_13C
13C




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7cj

van-lay283




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 7ck

van-lay293.1.fid




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 8cc




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 8dd




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 8de




SUPPORTING INFORMATION




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 9ab



SUPPORTING INFORMATION


LAY_43_13C
13C



SUPPORTING INFORMATION


¹H and ¹³C NMR spectra of the compound 9cb

van-lay3911.1.fid




SUPPORTING INFORMATION

LAY039_13C_01.12_longtime
13C




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 9db



SUPPORTING INFORMATION


LAY_41_13C
13C



SUPPORTING INFORMATION


¹H and ¹³C NMR spectra of the compound 9de

VAN-LAY494.1.fid



SUPPORTING INFORMATION


LAY049_13C
13C



SUPPORTING INFORMATION


¹H NMR and ¹³C spectrum of the compound 10cb

van-lay402.1.fid



SUPPORTING INFORMATION


Lay-40_C13.1.f13



SUPPORTING INFORMATION


¹H NMR and ¹³C spectrum of the compound 11dd

van-lay473.1.fid



SUPPORTING INFORMATION


BA078264-139-C13.1.fid




SUPPORTING INFORMATION

¹H and ¹³C NMR spectra of the compound 12b

lay-002.1.fid




SUPPORTING INFORMATION



SUPPORTING INFORMATION


¹H and ¹³C NMR spectra of the compound 12d

van-lay-0042



SUPPORTING INFORMATION


LAY004_T_C13.1.fid



SUPPORTING INFORMATION


¹H and ¹³C NMR spectra of the compound 14b

Lay_010_H-3.fid




SUPPORTING INFORMATION

lay810_C13.1.fid



SUPPORTING INFORMATION

¹H and ¹³C NMR spectrum of the compound 15e



SUPPORTING INFORMATION

Lay-50_C13.1.fid

— 131.55
— 127.95
— 123.97

— 63.25

— 52.33

— 28.65

